Literature DB >> 26971179

In vitro activity of tedizolid against linezolid-resistant staphylococci and enterococci.

Stephanie L Silva-Del Toro1, Kerryl E Greenwood-Quaintance1, Robin Patel2.   

Abstract

The tedizolid MIC of 27 clinical isolates of linezolid-resistant staphylococci and enterococci was determined. Tedizolid MICs were ≥1μg/mL and were 4- to 32-fold lower than those of linezolid. Linezolid resistance mechanisms included G2576T 23S rRNA gene and rplC and rplD mutations.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial resistance; Linezolid resistance; Multidrug resistance; Tedizolid resistance; Vancomycin resistant

Mesh：

Substances：

Year:  2016        PMID： 26971179      PMCID： PMC8067670          DOI： 10.1016/j.diagmicrobio.2016.02.008

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  18 in total

1.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

2.  Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances.

Authors:  Silke Besier; Albrecht Ludwig; Johannes Zander; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

3.  A T2504A mutation in the 23S rRNA gene responsible for high-level resistance to linezolid of Staphylococcus epidermidis.

Authors:  Apostolos Liakopoulos; Charalambos Neocleous; Dimitra Klapsa; Maria Kanellopoulou; Iris Spiliopoulou; Kostas D Mathiopoulos; Evangelos Papafrangas; Efi Petinaki
Journal:  J Antimicrob Chemother       Date:  2009-05-09       Impact factor: 5.790

4.  Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2009-01-22       Impact factor: 5.790

5.  Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Authors:  J Prystowsky; F Siddiqui; J Chosay; D L Shinabarger; J Millichap; L R Peterson; G A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

6.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Authors:  S M Swaney; H Aoki; M C Ganoza; D L Shinabarger
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 8.  Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Ronald N Jones
Journal:  Drug Resist Updat       Date:  2014-04-06       Impact factor: 18.500

9.  Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin.

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-10-05       Impact factor: 5.191

Review 10.  The emerging problem of linezolid-resistant Staphylococcus.

Authors:  Bing Gu; Theodoros Kelesidis; Sotirios Tsiodras; Janet Hindler; Romney M Humphries
Journal:  J Antimicrob Chemother       Date:  2012-09-04       Impact factor: 5.758
View more
  6 in total

1.  Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.

Authors:  Kyung-Hwa Park; Kerryl E Greenwood-Quaintance; Jayawant Mandrekar; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

Review 2.  Global Emergence and Dissemination of Enterococci as Nosocomial Pathogens: Attack of the Clones?

Authors:  Ana M Guzman Prieto; Willem van Schaik; Malbert R C Rogers; Teresa M Coque; Fernando Baquero; Jukka Corander; Rob J L Willems
Journal:  Front Microbiol       Date:  2016-05-26       Impact factor: 5.640

Review 3.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

Review 4.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447

5.  Linezolid Resistance in Enterococcus faecalis Associated With Urinary Tract Infections of Patients in a Tertiary Hospitals in China: Resistance Mechanisms, Virulence, and Risk Factors.

Authors:  Xiaoyu Ma; Fan Zhang; Bing Bai; Zhiwei Lin; Guangjian Xu; Zhong Chen; Xiang Sun; Jinxin Zheng; Qiwen Deng; Zhijian Yu
Journal:  Front Public Health       Date:  2021-02-05

6.  In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid.

Authors:  Johanna Marcela Vanegas Múnera; Ana María Ocampo Ríos; Daniela Montoya Urrego; Judy Natalia Jiménez Quiceno
Journal:  Braz J Infect Dis       Date:  2017-04-19       Impact factor: 3.257
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.